SAT0686 Major adverse cardiovascular events: risk factors in patients with ra treated with tofacitinib
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.2434
Abstract: Background Patients (pts) with RA have increased risk of myocardial infarction (MI) and stroke that cannot be completely explained by traditional cardiovascular (CV) risk factors. Tofacitinib is an oral JAK inhibitor for the treatment of… read more here.
Keywords: pfizer inc; risk; mace; mace risk ... See more keywords